Skip to main content
Figure 7 | Nutrition & Metabolism

Figure 7

From: Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

Figure 7

Linear fit of change from Baseline at Day 90 in ADAS-Cog score and log transformed post-dose serum BHB levels in the per protocol population stratified by APOE4 carriage status. Red symbols represent subjects taking AC-1202. Blue symbols represent subjects taking Placebo. Circles and squares indicate dosage compliant subjects, crosses represent non-compliant subjects. The solid lines represent the linear fit in the per protocol population. The dashed lines represent the linear fit in the dosage compliant sub-population of the per protocol population. A) A significant correlation was found in the per protocol population between serum BHB levels and change in ADAS-Cog on Day 90. B) A significant correlation was found in E4(-) per protocol subjects between serum BHB levels and change in ADAS-Cog on Day 90. C) No significant correlation was found in E4(+) per protocol subjects between serum BHB levels and change in ADAS-Cog on Day 90. In each case the linear fit of the dosage compliant subgroup is very similar to the overall per protocol population.

Back to article page